Frontiers in HIV Research

Frontiers in HIV Research

Volume: 1

Advances in HIV Treatment

Indexed in: EBSCO.

Advances in HIV Treatment: HIV Enzyme Inhibitors and Antiretroviral Therapy presents comprehensive and updated information on drug therapies used to treat and manage HIV infection in human patients. ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Protease Enzyme Inhibition

Pp. 75-96 (22)

Rebecca A. Sumner, Cindy J. Bednasz, Qing Ma and Gene D. Morse


The protease inhibitors are a potent, durable class of antiretroviral agents recommended as preferred initial therapy for the treatment of HIV-1 infection in combination with a nucleoside/nucleotide reverse transcriptase inhibitor. These agents play a critical role as salvage therapy in treatment-experienced patients with extensive antiretroviral drug exposure given their high genetic barrier to drug resistance. Each antiretroviral within this class is unique in virologic potency, drug-drug interaction potential, pharmacokinetic characteristics and adverse effect profile. This chapter will summarize and review protease inhibitors currently available on the market and provide guidance for the application of their use in clinical practice.


Protease Inhibitor, Antiretroviral Therapy, Pharmacogenomics, Lopinavir, Ritonavir, Saquinavir, Darunavir, Atazanavir, Fosamprenavir, Indinavir, Nelfinavir, Tipranavir.


Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, USA.